Current HIV drugs usually act on enzymes needed by the virus throughout its survival. But no drug targets the outermost layer of the virus named the capsid, which protects the genetic material delivered into the host.
Royal Free London NHS Foundation Trust and Teesside University researchers helped organize a ‘hackathon’ on 4 and 5 July 2018 at Brunel University in London with an aim to develop virtual reality (VR) tools for patients.
Researchers from South Ural State University (SUSU) found that man has been suffering from Hepatitis B since the Bronze Age with the help of viral traces in the genomes of ancient people. To understand how some of the ancient diseases spread and to find out how they might behave in the future, an international collaboration between researchers had been analyzing DNA of the relics of ancient people found in areas from Mongolia to Europe for several years.
In a joint venture, German biopharmaceutical firm BioNTech and Genevant Sciences, a genetic disorder therapeutics maker plan to develop mRNA therapy programmes targeting rare diseases with severely deficient medical attention.
Sanction of a single 300mg dose of GlaxoSmithKline’s tafenoquine in patients 16 years and above for the "radical cure" of malaria was advocated by an FDA advisory committee on finding significant evidence for its efficacy and safety.
Dr. Lionel Piroth and Dr. Marine Jacquier from the Centre Hospitalier Universitaire in Dijon reported in the New England Journal of Medicine, “A 35-year-old French woman presented to the emergency department with weakness, a feeling of electric shocks in both legs, and repeated falls; She reported that the symptoms had been progressing, and she noted that she had had difficulty riding her horse for the preceding three months.”
Despite the looming crises, Novartis will be shutting down antimicrobial research at its Novartis Institutes for Biomedical Research campus in Emeryville, California. There will be a loss of 140 jobs and the current projects will be put up for sale. This company was working on phase 2 clinical trial of LYS228 against complicated urinary tract infections and complicated intra-abdominal infections. The work on anti-dengue drugs and anti-malaria drugs (KAF156 and KAE609) were already in pipeline.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.